MetVital, Inc.
MetVital is a clinical-stage biopharmaceutical company focused on developing metabolic therapies to improve cellular metabolism and address fatigue-related conditions such as ME/CFS, Long COVID, Cancer Related Fatigue, ALS, and Parkinson’s Disease. They have developed and patented a small molecule called AEO that modulates metabolism towards a normal state, reducing inflammation, enhancing mitochondrial function, and increasing cellular energy. The company collaborates with NIH and other institutions, and their lead drug candidate AEO is in Phase 2 trials for glioblastoma multiforme and has received FDA Fast Track designation.
Industries
Nr. of Employees
small (1-50)
MetVital, Inc.
MetVital, Inc. 3830 Valley Centre Drive Suite 705-561 San Diego, CA 92130
Products
Investigational oxaloacetate‑derived small-molecule candidate (investigational drug)
An investigational small-molecule metabolite derived from oxaloacetate developed to modulate cellular metabolism (increase mitochondrial biogenesis and redox balance, reduce inflammatory signaling and glycolytic metabolism).
Investigational oxaloacetate‑derived small-molecule candidate (investigational drug)
An investigational small-molecule metabolite derived from oxaloacetate developed to modulate cellular metabolism (increase mitochondrial biogenesis and redox balance, reduce inflammatory signaling and glycolytic metabolism).
Services
Case-by-case evaluation and potential provision of investigational drug to patients outside clinical trials when criteria are met; requires physician request, IRB approvals, and compliance with safety reporting.
Case-by-case evaluation and potential provision of investigational drug to patients outside clinical trials when criteria are met; requires physician request, IRB approvals, and compliance with safety reporting.
Expertise Areas
- Clinical trial management
- Small-molecule metabolic therapy development
- Preclinical pharmacology and animal models
- Regulatory affairs and IND strategy
Key Technologies
- Small-molecule metabolic modulators
- Modulation of glutamate-related metabolism
- Mitochondrial biogenesis modulation
- Redox balance modulation (NAD+/NADH)
News & Updates
MetVital, Inc. Announces Collaboration with the NIH in the Epilepsy Therapy Screening Program (ETSP)
MetVital announces collaboration with NIH's NINDS in the ETSP to evaluate AEO's potential for epilepsy treatment.
FDA has granted Fast Track designation to AEO for the treatment of newly diagnosed glioblastoma multiforme.
FDA has cleared the IND application for AEO to proceed with Phase 2 testing for glioblastoma multiforme.
MetVital, Inc. Announces Collaboration with the NIH in the Epilepsy Therapy Screening Program (ETSP)
MetVital announces collaboration with NIH's NINDS in the ETSP to evaluate AEO's potential for epilepsy treatment.
FDA has granted Fast Track designation to AEO for the treatment of newly diagnosed glioblastoma multiforme.
FDA has cleared the IND application for AEO to proceed with Phase 2 testing for glioblastoma multiforme.